CAPÍTULO 4: Manifestaciones extra musculoesqueléticas en espondiloartritis axial 1: uveítis y psoriasis

Vanesa Cosentino

Vanesa Cosentino Hospital Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina

Palabras clave: espondiloartritis axial, uveítis, psoriasis

Resumen

Aunque la inflamación axial y el daño estructural son las características principales de la espondiloartritis axial (EspAax), muchos pacientes pueden presentar manifestaciones periféricas (entesitis, dactilitis y artritis) y dado que son enfermedades sistémicas, también pueden presentarse manifestaciones extra musculoesqueléticas (MEM) (uveítis, psoriasis, enfermedad inflamatoria intestinal, compromiso pulmonar, cardiovascular, renal, neurológico, etc.) concomitantes1-2. La presencia de una o más MEM puede afectar el pronóstico de la EspA, la calidad de vida y la productividad laboral de los pacientes, así como también tener influencia en la decisión del tratamiento3. A continuación se describen las características de la uveitis y la psoriasis en pacientes con EspAax.

Biografía del autor/a

Vanesa Cosentino, Hospital Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina

Hospital Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina

Citas

I. Rudwaleit M, Landewé R, Van Der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): Classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68(6):770-776.

II. de Winter JJ, van Mens LJ, van der Heijde D, Landewé R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: A meta-analysis. Arthritis Res Ther. 2016;18(1):1-11.

III. Stolwijk C, Van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis. A systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65-73.

IV. Banares A, Hernández-García C, Fernández-Gutiérrez B, Jover JA. Eye involvement in the spondyloarthropathies. Rheumatic Disease Clinics of North America. 1998;24(4):771-784.

V. Jabs DA, Nussenblatt RB, Rosenbaum JT, Atmaca LS, Becker MD, Brezin AP, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509-516.

VI. D’Ambrosio E, La Cava M, Tortorella P, Gharbyia M, Campanella M, Iannetti L. Clinical features and complications of the HLA-B27-associated acute anterior uveitis: a meta-analysis. Semin Ophthalmol. 2017;32(6):689-701.

VII. Rademacher J, Poddubnyy D, and Pleyer U. Uveitis in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020;12.

VIII. Gritz DC and Wong IG. Incidence and prevalence of uveitis in Northern California: The Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491-500.

IX. Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis: a systematic review. Front Med (Lausanne). 2021;8.

X. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: A systematic literature review. Ann Rheum Dis. 2008;67(7):955-959.

XI. Linssen A, Rothova A, Valkenburg HA, Dekker-Saeys AJ, Luyendijk L, Kijlstra A, et al. The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27. Invest Ophthalmol Vis Sci. 1991;32(9):2568-2578.

XII. Rosenbaum JT. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol. 2015;34(6):999-1002.

XIII. J. T Rosembaum. Characterization of uveitis associated with spondyloarthritis. J Rheumatology. 1989;16(6):792-796.

XIV. Gevorgyan O, Riad M, Sarran RD, Merrill PT, Block JA, Castrejon I. Anterior uveitis in patients with spondyloarthropathies in a single US academic center: a retrospective study. Rheumatol Int. 2019;39(9):1607-1614.

XV. Yang P, Wan W, Du L, Zhou Q, Qi J, Liang L, et al. Clinical features of HLA-B27-positive acute anterior uveitis with or without ankylosing spondylitis in a Chinese cohort. Br J Ophthalmol 2018;102:215-219.

XVI. Akshat P, Ravindran V. Ocular manifestations of spondyloarthritis. Mediterr J Rheumatol. 2023 31;34(1):24-29.

XVII. Smith W. Gender and spondyloarthropathy-associated uveitis. J Ophthalmol. 2013; 2013:928264

XVIII. Singh G, Lawrence A, Agarwal V, Misra R, Aggarwal A. Higher prevalence of extra-articular manifestations in ankylosing spondylitis with peripheral arthritis. J Clin Rheumatol. 2008;14(5):264-6.

XIX. Sykes M, Hamilton L, Jones C, Gaffney K. Prevalence of axial spondyloarthritis in patients with acute anterior uveitis: a cross-sectional study utilising MRI. RMD Open. 2018 24;4(1): e000553

XX. van Bentum R, Verbraak F, Wolf S, Ongkosuwito J, Boers M, Tan S, et al. High prevalence of previously undiagnosed axial spondyloarthritis in patients referred with anterior uveitis and chronic back pain: The SpEYE Study. J Rheumatol. 2022; 49(7):680-687

XXI. Haroon M, O’Rourke M, Ramasamy P, Murphy CC, and FitzGerald O. A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: The DUET (Dublin Uveitis Evaluation Tool). Ann Rheum Dis. 2015;74(11):1990-1995.

XXII. Espinosa G, Muñoz-Fernández S, García Ruiz de Morales J, Herreras J, Cordero-Coma M. Documento de recomendaciones de tratamiento de la uveítis anterior no infecciosa. Med Clin (Barc). 2017 20;149(12): 552.e1-552.e12

XXIII. Harthhan J, Opitz D, Fromstein S, Morettin C. Diagnosis, and treatment of anterior uveitis: optometric management. Clin Optom (Auckl). 2016 31; 8:23-35.

XXIV. Kiddee W, Trope G, Sheng L, Beltran-Agullo L, Smith M, Strungaru H. et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58(4):291-310

XXV. Gómez-Gómez A, Loza E, Rosario M, Espinosa G, García Ruiz de Morales JM, Herreras JM, et al. Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis A systematic literature review. Medicine (Baltimore). 2017; 96(42): e8045

XXVI. Bachta A, Kisiel B, Tłustochowicz M, Raczkiewicz A,Rekas M, Tłustochowicz W. High efficacy of methotrexate in patients with recurrent idiopathic acute anterior uveitis: a prospective study. Arch Immunol Ther Exp (Warsz). 2017; 65(1):93-97

XXVII. Wu D, Guo Y, Xu N, Zhao S, Hou L, Jiao T, et al. Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord. 2015 10;16(1):19.

XXVIII. Levy-Clarke G, Jabs D, Read R, Rosenbaum J, Vitale A, Van Gelder R. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785-96. e3

XXIX. Goto H, Zako M, Namba K, Hashida N, Kaburaki T, Miyazaki M, et al. Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II Trials. Ocul Immunol Inflamm. 2019;27(1):40-50

XXX. Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68(5):696-701.

XXXI. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52(8):2447-51

XXXII. Brito-Zeron P, Pérez-Álvarez R, Ramos-Casals M, BIOGEAS study group. Etanercept and uveitis: Friends or foes? Curr Med Res Opin. 2015. PMID: 25438042

XXXIII. van Bentum R, Heslinga S, Nurmohamed M, Gerards, Griep N, Koehorst C, et al. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with Golimumab- The GO- EASY Study. J Rheumatol. 2019; 46(2):153-159.

XXXIV. van der Horst-Bruinsma I, Robinson P, Favalli E, Verbraak F, Kim M, Kumke T, et al. Certolizumab pegol treatment in patients with axial-spondylarthritis-associated acute anterior uveitis: a narrative review. Rheumatol Ther. 2022;9(6):1481-1497

XXXV. van der Horst-Bruinsma I, van Bentum R,Verbraak F, Rath T, Rosenbaum J, Misterska-Skora M, Hoepken B, et al. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open. 2020;6(1): e001161

XXXVI. Dick A, Tugal-Tutkun I, Foster S, Zierhut M, Liew M, Bezlyak V, et al. Secukinumab in the treatment of noninfectious uveitis. Results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777-87.

XXXVII. Feld J, Yang Ye J, Chandran V, Inman R, Haroon N, Cook R, et al. Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? Rheumatology (Oxford). 2020 1;59(6):1340-1346.

XXXVIII. Stolwijk C, van Tubergen A, Castillo-Ortiz J, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65-73.

XXXIX. Poddubnyya D, Jadonb D, van den Boschc F, Meased P, Gladman D. Axial involvement in psoriatic arthritis: An update for rheumatologists. Semin Arthritis Rheum. 2021;51(4):880-887

XL. Fragoulis G, Pappa M, Evangelatos G, Iliopoulos A, Sfikakis P, Tektonidou M.G. Axial psoriatic arthritis and ankylosing spondylitis: same or different? A real-world study with emphasis on comorbidities. Clin Exp Rheumatol. 2022;40(7):1267-1272.

XLI. Pérez Alamino R, Maldonado Cocco J, Arturi P , Citera G, Berman A, Graf C, et al. En representación del Grupo RESPONDIA. Características diferenciales entre espondilitis anquilosante pura y espondilitis psoriásica en pacientes argentinos. Rev Argen Reumatol 2021;4.

XLII. Lorenzin M, Ortolan A, Vio S, Cozzi G, Scapin V, De Conti G, et al. Psoriasis and imaging progression in early axial spondyloarthritis: results from a 48-month follow-up (Italian arm of SPACE study). Rheumatology (Oxford). 2022 30;61(6):2375-2387.

XLIII. López-Medina C, Ortega-Castro R, Castro-Villegas M.C, Font-Ugalde P, Puche-Larrubia M.A, Gómez-García I, et al. Axial and peripheral spondyloarthritis: does psoriasis influence the clinical expression and disease burden? Data from REGISPONSER registry. Rheumatology (Oxford). 2021 2;60(3):1125-1136.

XLIV. Solmaza D, Bakircia S, Jibrib Z, Sampaio M, Karsha J, Aydin S. Psoriasis is an independent risk factor for entheseal damage in axial spondyloarthritis. Semin Arthritis Rheum. 2020;50(1):42-47.

XLV. Ciurea A, Götschi A, Kissling S, Bernatschek A, Bürki K, Exer P, et al. Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry. RMD Open. 2023;9(2): e002956

XLVI. Lucasson F, Richette P, Aouad K, Ryussen-Witrand A, Wendling D, Fautre B, et al. Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years. RMD Open. 2022;8(1): e001986.

XLVII. Poddubnyy D, Baraliakos X, Van den Bosch F, Braun J, Coates L, Chandran V, et al. Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Ther Adv Musculoskelet Dis. 2021;18:13:1759720X211057975.